These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 465827)

  • 21. Drug kinetics and drug resistance in optimal chemotherapy.
    Costa MI; Boldrini JL; Bassanezi RC
    Math Biosci; 1995 Feb; 125(2):191-209. PubMed ID: 7881194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1995; 12(1):55-69. PubMed ID: 7594878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?
    Ledzewicz U; Schättler H
    Cancer Lett; 2017 Aug; 401():74-80. PubMed ID: 28323033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal control for a cancer chemotherapy problem with general growth and loss functions.
    Murray JM
    Math Biosci; 1990 Mar; 98(2):273-87. PubMed ID: 2134507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort.
    Michor F; Beal K
    Cell; 2015 Nov; 163(5):1059-1063. PubMed ID: 26590416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling and optimization of combined cytostatic and cytotoxic cancer chemotherapy.
    Villasana M; Ochoa G; Aguilar S
    Artif Intell Med; 2010 Nov; 50(3):163-73. PubMed ID: 20620035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention of resistance to chemotherapy in the therapeutic strategy for cancer].
    Droz JP
    Bull Cancer; 1994 Dec; 81 Suppl 2():91s-94s. PubMed ID: 7727869
    [No Abstract]   [Full Text] [Related]  

  • 28. Mathematical analysis of cancer chemotherapy: the effects of chemotherapeutic agents on the cell cycle traverse.
    Chuang SN; Soong TT
    Bull Math Biol; 1978; 40(4):499-512. PubMed ID: 678695
    [No Abstract]   [Full Text] [Related]  

  • 29. The dynamics of cell proliferation.
    Moxnes JF; Haux J; Hausken K
    Med Hypotheses; 2004; 62(4):556-63. PubMed ID: 15050107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal drug regimens in cancer chemotherapy: a multi-objective approach.
    Batmani Y; Khaloozadeh H
    Comput Biol Med; 2013 Dec; 43(12):2089-95. PubMed ID: 24290925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy dosing part II: alternative approaches and future prospects.
    Kaestner SA; Sewell GJ
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):99-107. PubMed ID: 17355104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapeutic treatments involving drug resistance and level of normal cells as a criterion of toxicity.
    Costa MI; Boldrini JL; Bassanezi RC
    Math Biosci; 1995 Feb; 125(2):211-28. PubMed ID: 7881195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemically triggered time delay activation chemotherapy for the treatment of cancer.
    Walker EH
    Perspect Biol Med; 1980; 23(3):424-38. PubMed ID: 6771745
    [No Abstract]   [Full Text] [Related]  

  • 34. Model for tumour growth with treatment by continuous and pulsed chemotherapy.
    Borges FS; Iarosz KC; Ren HP; Batista AM; Baptista MS; Viana RL; Lopes SR; Grebogi C
    Biosystems; 2014 Feb; 116():43-8. PubMed ID: 24333154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation.
    Clairambault J
    IEEE Eng Med Biol Mag; 2008; 27(1):20-4. PubMed ID: 18270046
    [No Abstract]   [Full Text] [Related]  

  • 36. The effects of chemotherapy on the morphology of solid tumours.
    Cooper EH
    Schweiz Med Wochenschr; 1974 Feb; 104(8):275-8. PubMed ID: 4814679
    [No Abstract]   [Full Text] [Related]  

  • 37. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
    Chandel NS; Avizonis D; Reczek CR; Weinberg SE; Menz S; Neuhaus R; Christian S; Haegebarth A; Algire C; Pollak M
    Cell Metab; 2016 Apr; 23(4):569-70. PubMed ID: 27076070
    [No Abstract]   [Full Text] [Related]  

  • 38. On the importance of sensitivity to the dose-effect relationship in chemotherapy.
    Jakobsen A; Mortensen LS
    Acta Oncol; 1997; 36(4):375-81. PubMed ID: 9247097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?
    Di Maio M; Gridelli C; Gallo C; Perrone F
    Nat Clin Pract Oncol; 2006 Mar; 3(3):114-5. PubMed ID: 16520781
    [No Abstract]   [Full Text] [Related]  

  • 40. A mathematical model for M-phase specific chemotherapy including the G0-phase and immunoresponse.
    Liu W; Hillen T; Freedman HI
    Math Biosci Eng; 2007 Apr; 4(2):239-59. PubMed ID: 17658926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.